drugset / Trial / NCT06717750
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Phase 1
Recruiting
102 enrolled
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
Timeline
- Start
- 2025-02-13
- Primary completion
- 2027-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CSCJC3456 | Unknown | 5 mg | Oral |
| Subject | CSCJC3456 | Unknown | 15 mg | Oral |
| Subject | CSCJC3456 | Unknown | 30 mg | Oral |
| Subject | CSCJC3456 | Unknown | 45 mg | Oral |
| Subject | CSCJC3456 | Unknown | 60 mg | Oral |
| Subject | CSCJC3456 | Unknown | 80 mg | Oral |
| Subject | CSCJC3456 | Unknown | 100 mg | Oral |